SEC Form 4	
------------	--

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pur

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or Sec	x = 30(n)	of the	e inves	siment C	ompany Ac	t of 194	40							
1. Name and Address of Reporting Person <sup>*</sup> GRYSKA DAVID W					2. Issuer Name and Ticker or Trading Symbol PDL BIOPHARMA, INC. [PDL1]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
				I									Director			10% Ov	ner		
(Last) (First) (Middle) 932 SOUTHWOOD BLVD.					3. Date of Earliest Transaction (Month/Day/Year) 08/19/2020								Officer ( below)	give title		Other (s below)	pecify		
(Street) INCLINE					4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
VILLAG	N	V	89451										rm filed by More than One Reporting						
(City)	(S	tate)	(Zip)																
		Ta	ble I - Non	-Deriva	tive S	ecuritie	es Ac	cquir	red, Di	sposed	of, or	r Ben	eficially	Owned					
Dat			2. Transac Date (Month/Da		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		n Dispose	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amoun Securities Beneficia Owned Fo Reported	ly	Form (D) or	: Direct r Indirect str. 4)	7. Nature of ndirect Beneficial Dwnership		
								Co	ode V	Amount		(A) or (D)	Price	Transactie (Instr. 3 a	ion(s)			(Instr. 4)	
Common stock 08/1				08/19/2	)/2020				A	25,82	25,826 <sup>(1)</sup> A		\$ <mark>0</mark>	245,337			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code	saction (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expira	te Exerci ation Da th/Day/Ye		of Securities		es Security	Derivative Security		erof e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exerc	cisable	Expiratior Date	Title		Amount or Number of Shares		Transaction(s) (Instr. 4)				
Stock Option (right to buy)	\$3.63	08/19/2020		A		118,671		08/19/	/2021 <sup>(2)</sup>	08/19/203		nmon ock	118,671	\$3.63	118,6	71	D		

## Explanation of Responses:

1. The restricted stock will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date.

2. The stock options will vest on the one year anniversary of the grant date, subject to acceleration of vesting upon a change in control or the Company filing a certificate of dissolution with the state of Delaware; provided that the recipient's continuous service has not terminated prior to such date.

## **Remarks:**

/s/ Nathan N. Kryszak,

Attorney-in-Fact for David W.

08/21/2020

<u>Gryska</u> \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.